ImmunityBio (IBRX) Current Assets (2014 - 2026)

ImmunityBio (IBRX) has 13 years of Current Assets data on file, last reported at $453.0 million in Q1 2026.

• Current Assets for Q1 2026 came in at $453.0 million, up 314.93% year-over-year; the trailing twelve-month figure through Mar 2026 was $453.0 million (up 314.93% YoY), and the FY2025 annual result was $314.9 million, up 70.58% from the prior year.
• Current Assets climbed to $453.0 million in Q1 2026 per IBRX's latest filing, from $314.9 million in the prior quarter.
• Over five years, Current Assets peaked at $453.0 million in Q1 2026 and troughed at $66.8 million in Q2 2023.
• A 5-year average of $206.0 million and a median of $195.7 million in 2024 frame the typical range for Current Assets.
• The sharpest annual moves came in 2022 and 2026: Current Assets slumped 57.95% in 2022, then jumped 314.93% in 2026.
• A 5-year view of Current Assets shows it stood at $140.6 million in 2022, then soared by 109.2% to $294.1 million in 2023, then tumbled by 37.23% to $184.6 million in 2024, then soared by 70.58% to $314.9 million in 2025, then soared by 43.85% to $453.0 million in 2026.
• Business Quant data shows IBRX's Current Assets at $453.0 million in Q1 2026, $314.9 million in Q4 2025, and $329.5 million in Q3 2025.